In brief
- Four Austrian scientific societies jointly endorse a quality-assured, risk-adapted national lung cancer screening programme, citing international evidence that low-dose computed tomography (LDCT) screening reduces lung cancer mortality.
- The position paper, published in Wiener klinische Wochenschrift, covers the target population, inclusion and exclusion criteria, diagnostics, quality assurance, programme organisation and multidisciplinary care.
- The recommendations draw on international evidence, current European guidelines and Austrian epidemiological and health economic data.
- The authors conclude that such a programme could reduce lung cancer mortality, detect more tumours at curable stages and improve the long-term care of people at high risk.
Late diagnosis in Austria as the starting point
The authors describe lung cancer as one of the leading causes of cancer-related death in Austria, and one that is frequently diagnosed at an advanced stage. They cite international studies in which structured LDCT screening reduced lung cancer mortality and increased the detection of early-stage, potentially curable disease.
The document is a joint position paper. Its recommendations rest on the published international evidence, on European guidelines and recommendations, and on Austrian figures for disease burden and health economics.
Radiology, pneumology, general practice and thoracic surgery wrote it together
Representatives of the four societies developed the recommendations jointly. Between them, these disciplines span the screening pathway, from identifying people at risk in primary care to reading the scans, working up positive findings and operating on screen-detected tumours.
The recommendations address the target population, programme organisation, quality assurance and national implementation. The results section of the abstract adds inclusion and exclusion criteria, requirements for diagnostics and multidisciplinary care to that list.
Eligibility criteria and costs are left to the full text
The societies endorse a programme that is risk-adapted, so that eligibility depends on a person’s risk of lung cancer. The abstract does not say how that risk is to be assessed: it gives no age range, no smoking-history threshold, no risk prediction model and no screening interval.
Austrian health economic data are listed among the sources of the recommendations, but the abstract reports no cost or cost-effectiveness figures. Readers who need the eligibility rules or the budget case will have to consult the full paper.
Lower mortality and earlier-stage detection as the stated aims
The authors conclude that the evidence supports a national programme, and they present the paper as a basis for health policy decisions in Austria.
“The available evidence supports the implementation of a national quality-assured lung cancer screening program in Austria.”Wass et al., Wiener klinische Wochenschrift (2026)
In their view, such a programme has the potential to reduce lung cancer mortality over the long term, to find more tumours at stages that can be cured and to improve the long-term care of people at high risk. The abstract gives no estimate of the effect a programme would have in Austria itself.
Sources
- Wiener klinische Wochenschrift. Implementierung eines nationalen Lungenkarzinom-Screening in Österreich (2026-09-18). doi.org
Featuring Lung Summit faculty
This study was co-authored by Lung Summit faculty Maximilian Hochmair.
This article was produced independently by the Lung Summit editorial team, without industry funding or input.
